2022
OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)
Petrov J, Al-Bawardy B, Gaidos J, Proctor D. OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA). Inflammatory Bowel Diseases 2022, 28: s75-s76. DOI: 10.1093/ibd/izac015.123.Peer-Reviewed Original ResearchIleal pouch-anal anastomosisPouch-anal anastomosisTotal proctocolectomyMedical therapyCrohn's diseaseChronic pouchitisRepeat surgeryAnal anastomosisAnatomic complicationsChronic antibiotic-refractory pouchitisAntibiotic-refractory pouchitisBiopsy-proven inflammationChronic steroid therapyEpisodes of pouchitisPre-pouch ileitisSymptoms of pouchitisAdverse postoperative outcomesRate of complicationsSurgery of choiceUlcerative colitis patientsTreatment of complicationsMulti-center studyThird of subjectsAcute pouchitisAnatomical complications
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis